Wealthspire Advisors (New York)’s TherapeuticsMD TXMD Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,200	Closed	-$42K	–	523
2022 Q1	$42K	Hold	2,200	–	–	﹤0.01%	426
2021 Q4	$39K	Buy	2,200 +1,400	+175%	+$42K	﹤0.01%	531
2021 Q3	$30K	Hold	800	–	–	﹤0.01%	576
2021 Q2	$48K	Buy	800 +148	+23%	+$8.97K	﹤0.01%	364
2021 Q1	$44K	Hold	652	–	–	﹤0.01%	699
2020 Q4	$39K	Buy	+652	New	+$44.5K	﹤0.01%	575
2019 Q1	–	Sell	-2	Closed	–	–	736
2018 Q4	$0	Buy	+2	New	+$488	﹤0.01%	919

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Wealthspire Advisors (New York)'s TXMD Position: Q2 2022 in Review

Wealthspire Advisors (New York) sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 2,200 shares — an estimated $42K sold.

Wealthspire Advisors (New York) first reported a position in TXMD in Q4 2018 and held it in 7 quarters. The position peaked at $48K in Q2 2021. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

Wealthspire Advisors (New York) reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
Wealthspire Advisors (New York) sold 2,200 TherapeuticsMD shares in Q2 2022, an estimated $42K.
Wealthspire Advisors (New York) first reported a position in TherapeuticsMD in Q4 2018 and held it in 7 quarters.
Wealthspire Advisors (New York)'s TherapeuticsMD position peaked at $48K in Q2 2021.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2022, filed 9 Aug 2022.